Price$1.83-1.21 (-39.80%)
2026-03-182026-06-22
News · 26 weeks46-25%
2025-12-282026-06-21
Mix2590d
- SEC Filings9(36%)
- Insider8(32%)
- Other5(20%)
- Earnings2(8%)
- Offering1(4%)
Latest news
25 items- PRLife Sciences Virtual Investor Forum Agenda Announced for June 24th & 25thNEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings
- PRIMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without ModificationOn track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer Novel immunotherapy technology demonstrating unprecedented IL-12 safety profile and extraordinary Phase 2 efficacy LAWRENCEVILLE, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the independent Data Monitoring Committee (iDMC) has recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with standard of care (SoC) neoa
- PRIMUNON to Present at the Life Sciences Investor Forum on June 25thLAWRENCEVILLE, N.J., June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON, will present at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on Thursday, June 25, 2026, at 12:00 p.m. ET. DATE: Thursday, June 25th, 2026TIME: 12:00 p.m. ETWebcast Registration Link HereAvailable for 1x1 meetings: Schedule 1x1 Meetings HERE This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event liv
- SECSEC Form S-8 filed by Imunon Inc.S-8 - Imunon, Inc. (0000749647) (Filer)
- SECSEC Form 8-K filed by Imunon Inc.8-K - Imunon, Inc. (0000749647) (Filer)
- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 4,089 shares, increasing direct ownership by 47% to 12,838 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERPresident and CEO Lindborg Stacy was granted 1,593 shares, increasing direct ownership by 44% to 5,235 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- SECImunon Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- PRIMUNON Announces Up to $10 Million Cash FinancingIncludes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports IMUNON's Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer LAWRENCEVILLE, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company has entered into definitive agreements with expected aggregate gross proceeds to the Company in the amount of $10 million. The transaction includes 250 shares of non-redeemable, non-convertible preferred stock for $2.5 million and two secured pr
- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 3,484 shares, increasing direct ownership by 66% to 8,749 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERDirector Pellizzari Christine A was granted 5,557 shares, increasing direct ownership by 215% to 8,142 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERDirector Dentzer James E was granted 11,148 shares, increasing direct ownership by 292% to 14,963 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERDirector Braun Donald P was granted 5,011 shares, increasing direct ownership by 116% to 9,319 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERDirector Fritz Frederick J. was granted 10,330 shares, increasing direct ownership by 274% to 14,097 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERPresident and CEO Lindborg Stacy was granted 1,491 shares, increasing direct ownership by 69% to 3,642 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- SECSEC Form 10-Q filed by Imunon Inc.10-Q - Imunon, Inc. (0000749647) (Filer)
- SECImunon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- PRIMUNON Reports First Quarter 2026 Financial Results and Provides Business UpdateIMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable Phase 2 data showing significant overall survival improvement FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported fin
- PRIMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, May 12, 2026 to discuss financial results for the first quarter ended March 31, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer. To participate in the call, please dial 800-715-9871 (U.S. and Canada/Toll Free) or 646-307-1963 (U
- SECImunon Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- SECSEC Form DEF 14A filed by Imunon Inc.DEF 14A - Imunon, Inc. (0000749647) (Filer)
- SECSEC Form 10-K filed by Imunon Inc.10-K - Imunon, Inc. (0000749647) (Filer)
- SECImunon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- PRIMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 StudyIMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clinical data show continued median overall survival improvement with IMNN-001 Enrollment in the OVATION 3 Study, IMUNON's Phase 3 pivotal trial for IMNN-001, remains ahead of plan supported by continued strong interest from principal investigators and the medical community Company to hold conference call today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunother
- PRIMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian CancerThe increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysis Patients treated with PARP inhibitor therapy in addition to IMNN-001 and standard of care chemotherapy demonstrated median increase in OS of 24.2 months Enrollment in IMUNON's Phase 3 pivotal trial for IMNN-001 remains ahead of plan, supported by continued strong interest from investigators and medical community LAWRENCEVILLE, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced final cl
IMNN FAQ
4 questionsWhere does IMNN stock trade?
Imunon Inc. (IMNN) is listed on NASDAQ.What sector and industry is IMNN in?
Imunon Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to IMNN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IMNN side-by-side with any of them on Quantisnow.How can I track IMNN on Quantisnow?
Quantisnow aggregates Imunon Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMNN to receive live email and push alerts on every new disclosure.